Blazar
Entrepreneur First '19Paris, FR · Founded 2019 · 1 known investors
Find your way into Blazar
316 people in our graph share verified history with the Blazar team — schools, employers, funds. One of them is your warm intro.
Blazar develops software and methods for biomedical and translational R&D teams to preserve the traceability, context, and interpretability of results, model outputs, and supporting evidence as data, models, instruments, and workflows change over time. It serves institutions working on biomarker programs, multi-site analysis, AI-enabled pathology, and translational research, and can be deployed on-premise, in private cloud, or within a controlled environment.
Also known as BLAZAR · Blazar SAS
Founders & leadership
Blazar was founded in 2019 by Dora Sabino and Renan Pereira.
Investors · 1
Company profile
researched Aug 2026Blazar (legally Blazar SAS, RCS Paris, SIREN 848056651) develops software and methods intended to help biomedical and translational R&D teams preserve continuity, traceability, and the conditions required to interpret results as data, models, instruments, pipelines, and conditions of use change. The company frames the core problem as one of degrading interpretability: results continue to circulate after the environment in which they were produced has evolved, so their meaning, context, and underlying assumptions become less explicit. Its stated application areas are biomarker programs, multi-site analytical environments, AI-enabled pathology, and translational workflows [0][1][2].
Functionally, the offering links each result to its underlying data, assumptions, versions, technical environment, and intended scope of use; records changes in methods, models, instruments, and pipelines; structures metadata and history for data lineage; brings heterogeneous results into a more coherent analytical framework; and supports human review and structured checkpoints in institutional, collaborative, or multi-site settings. Deployment can occur on-premise, in private cloud, or within a controlled environment, with the company stating that institutions retain control and that there is no data reuse and no ambiguity over intellectual property [0][1].
A French startup directory lists the company under the name BLAZAR in the health/biotech sector (Health Tech sub-sector, B2B model, web platform and mobile app activity), describing it as a software platform for producing predictive models in oncology, with an emphasis on immunotherapy response — noting low response rates (20–30% of patients), severe adverse effects, and high cost as the problems addressed. That listing records a creation year of 2018, an address in Saint-Mandé (Île-de-France), a headcount band of 2–10, registered capital of €0.1K, and one founder, Dora Carrasco Sabino (CEO) [5].
Founding story
A French startup directory records BLAZAR's creation in 2018 and lists Dora Carrasco Sabino as sole founder and CEO from January 2019; her prior background includes a Licenciatura from Universidade de Lisboa with skills in cell and molecular biology, an R&D scientist / project manager role at tebu-bio (February 2017 – September 2018), and participation in the Entrepreneur First EFPA1 cohort (October 2018 – February 2019) [5].
Business model
B2B software and methods sold to institutions, deployed on-premise, in private cloud, or inside a customer-controlled environment; engagements are described as operating within clearly defined scopes and formalised requests inside existing institutional environments and their access constraints [0][1][2][5].
Traction
The About page states that Blazar has participated in research, innovation, and support programs and has been referenced in public communications related to those activities, but the specific programs and references are not named in the retrieved page. No customers, revenue, or funding figures are disclosed in the available sources; a French startup directory shows no total funds raised and a headcount band of 2–10 [2][5].
Latest developments
The website carries a 2026 copyright notice and the privacy policy is dated March 2026, indicating the site reflects a current positioning around results traceability and interpretability rather than the earlier oncology prediction platform framing [0][1][2][3].
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
The company emphasises human oversight at every stage, no autonomous decisions, no diagnostic or clinical decision-making use, no data reuse, vendor neutrality, and deployment inside institutional control boundaries. It states it does not replace expert judgment and makes no promises of outcomes [0][1][2].
Technology
Software and methods that attach context to results — data, assumptions, versions, technical environment, and intended scope of use — and record changes to methods, models, instruments, and pipelines to preserve continuity of interpretation. The approach may incorporate statistical analysis, model outputs, and AI, positioned within a broader framework for structuring, reviewing, and following results over time rather than for autonomous decision-making. Data lineage is supported through structured metadata and history. The website is built on Webflow, with Cloudflare for security/bot protection and Proton for email hosting [0][1][2][3][5].
Go-to-market
Direct, meeting-led institutional engagement: the website invites prospective partners to request an initial meeting describing their context, scope, and the changes they need to structure or document, after which a discussion is organised within an appropriate framework. The company positions itself as vendor-neutral and states that partner organisations retain control over interpretation, decisions, and downstream use [0][1][2].
Biomedical and translational R&D teams and institutions managing sensitive workflows in biomarker programs, multi-site analysis, AI-enabled pathology, and translational research [0][1][2].
Geography
France. Blazar SAS is registered with RCS Paris (SIREN 848056651) with a registered office at 128 rue La Boétie, 75008 Paris; a French startup directory lists an Île-de-France address at 5 Avenue du Général de Gaulle, 94160 Saint-Mandé [0][1][2][3][5].
History
According to the company's About page, Blazar emerged from work in artificial intelligence applied to pathology, biomarkers, and translational modelling. Its early work explored predictive and clinically oriented approaches in oncology research during the rise of precision medicine and data-driven methods, which exposed challenges of heterogeneity, reproducibility, and interpretation in complex biomedical workflows. This led to the current direction: making the conditions for interpreting results explicit and supporting traceability, structured review, and responsible use over time. A French registry-derived listing describes the earlier positioning as a software platform for predictive models in oncology aimed at immunotherapy response, and records a change of company officers in March 2021 [2][5].
Risks & controversies
The company repeatedly states that its technologies and solutions are under research and development, are not CE-marked under EU Regulation 2017/745, and are not intended for diagnosis or clinical decision-making — limiting current deployment to R&D and translational use. Capabilities are said to depend on project scope, implementation choices, and partner implementation. No funding, customer, or revenue data is publicly disclosed in the available sources, and the public description of the business has shifted materially from the oncology immunotherapy-prediction framing found in a French startup directory to the current traceability/interpretability positioning [0][1][2][5].
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsFrench BODACC records show a 'changement de dirigeants' (change of directors) filing for BLAZAR in March 2021.
Dora Carrasco Sabino is listed as part of the EFPA1 cohort at Entrepreneur First from October 2018 to February 2019, immediately before becoming CEO of Blazar in January 2019.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Blazarblazar.ai · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Blazar do?
- Paris-based Blazar builds software and methods that keep biomedical and translational R&D results traceable and interpretable over time.
- Who founded Blazar?
- Blazar was founded by Dora Sabino, Renan Pereira in 2019.
- Who are Blazar's investors?
- Blazar's investors include Entrepreneur First.
- Where is Blazar headquartered?
- Blazar is headquartered in Paris, FR.